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A B S T R A C T
Label-free cellular assays using a biosensor provide new opportunities for studying G protein-coupled receptor
(GPCR) signaling. As opposed to conventional in vitro assays, integrated receptor-mediated cellular responses are
determined in real-time rather than a single downstream signaling pathway. In this study, we examined the
potential of a label-free whole cell impedance-based biosensor system (i.e. xCELLigence) to study the pharma-
cology of one GPCR in particular, the mGlu2 receptor. This receptor is a target for the treatment of several
psychiatric diseases such as schizophrenia and depression.
After optimization of assay conditions to prevent interference of endogenous glutamate in the culture
medium, detailed pharmacological assessments were performed. Concentration-response curves showed a
concentration-dependent increase in impedance for agonists and positive allosteric modulators, whereas re-
ceptor inhibition by an antagonist or negative allosteric modulator resulted in a concentration-dependent de-
crease in cellular impedance. Interestingly, constitutive receptor activity was observed that was decreased by
LY341495, which therefore behaved as an inverse agonist here, a property that was heretofore unappreciated.
This was confirmed by concentration-dependent modulation of LY341495 potency and efficacy by a allosteric
modulators.
In summary, the use of the xCELLigence system to study mGlu2 receptor pharmacology was validated. This is
the first class C GPCR to be characterized extensively by such method, opening new avenues to study receptor
pharmacology including inverse agonism and demonstrating its value for future drug discovery efforts of mGlu
receptors as well as other GPCRs.
1. Introduction
Traditionally, drug discovery at G protein-coupled receptors
(GPCRs) has been based on screening drug candidates using functional
in vitro endpoint-based assays in which the ability of a compound to
activate or inhibit a certain pathway is determined. Over the last
decade on the other hand the use of label-free cellular assays has greatly
increased [1,2]. These assays, typically using a biosensor, measure
cellular responses upon ligand stimulation, which result in morpholo-
gical changes of the whole cell [3]. Thereby some of the caveats of
traditional endpoint assays are circumvented: no labels (e.g. radio-
active, fluorescent) or reporter genes are required and measurements
can be performed continuously [4]. Cell types used include re-
combinant cell lines, cell lines endogenously expressing the target of
interest and even patient-derived cells [5]. Label-free assays used to
study GPCR responses are mostly based on measurement of changes in
cell morphology either optically, such as EPIC (Corning Inc.) or by
changes in impedance, such as xCELLigence (ACEA Biosciences) [1,6].
These systems have proven valuable in studying GPCR pharmacology in
different cell lines [7–9].
Being a presynaptic regulator of glutamate release, the mGlu2 re-
ceptor has been of great interest in drug discovery over the last decade.
This receptor, a class C GPCR, has emerged as therapeutic target for
various psychiatric diseases amongst which schizophrenia, depression
and anxiety, which are characterized by glutamatergic dysfunction
[10,11]. A variety of glutamate-like agonists that can dampen gluta-
mate hyperfunction was developed, of which LY2140023 of Eli Lilly, a
prodrug of LY404039 showed improvement in positive and negative
symptoms in schizophrenic patients, which could not be confirmed in
later clinical studies [12,13]. Inhibition of the mGlu2 receptor can be
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beneficial for glutamate hypofunction in depression, and when con-
sidering the orthosteric binding site antagonist LY341495 has been the
most studied for this purpose [14,15]. Since the orthosteric site is
highly conserved among the mGlu receptor subtypes and medicinal
chemistry of orthosteric ligands is constrained to hydrophilic glutamate
derivatives, drug development efforts later shifted to allosteric mod-
ulators for the mGlu2 receptor, which have been shown to bind in a less
evolutionary conserved binding site within the transmembrane domain
[16–18]. This allosteric binding site is more hydrophobic and allows
more chemical diversity [19]. Therefore, subtype selectivity is obtained
relatively easier and allosteric modulators are more prone to cross the
blood brain barrier due their increased lipophilicity. Allosteric mod-
ulators enhance or inhibit the affinity and/or efficacy of the en-
dogenous agonist glutamate and some positive allosteric modulators
(PAMs) also show intrinsic efficacy, referred to as PAM agonism [20].
Reference PAMs in the field include JNJ-40068782 [21], BINA [22] and
JNJ-46281222 [23]. Two PAMs entered clinical trials, AZD8529 of
AstraZeneca and JNJ-40411813 (also known as ADX71149) from
Janssen/Addex [24–29]. A number of mGlu2 negative allosteric mod-
ulators (NAMs) have been characterized in vivo, including a recent
series of NAMs from Janssen and RO4491533 and decoglurant from
Roche, of which the latter also advanced into clinical trials [30–33].
Taken together, discovery efforts have resulted in a great diversity of
selective and high affinity mGlu2 ligands, but no compounds have
successfully passed clinical evaluation.
To increase the understanding on ligand-induced mGlu2 responses,
we evaluated in this study the use of the label-free impedance-based
xCELLigence system to study the pharmacology of the mGlu2 receptor
in vitro. A benefit of this biosensor is that experiments are performed
under more relevant conditions than most traditional assays (i.e. living
cells at 37 °C in culture medium). After optimization of pre-treatment
conditions to reduce the concentration of endogenous glutamate in the
assay medium, responses of an agonist, antagonist, PAM and NAM were
studied. Furthermore, we evaluated constitutive receptor activity by
using antagonist/inverse agonist and NAM pre-treatment experiments.
Finally, the effects of a PAM or NAM on agonist efficacy were studied.
Taken together, biosensor-based label-free systems are helpful in
studying (novel) mGlu2 pharmacology in a more physiologically re-
levant environment. Our studies may be equally relevant for other class
C GPCRs.
2. Materials and methods
2.1. Materials
LY354740, RO4491533 and JNJ-46281222 were synthesized at
Janssen Research and Development (Toledo, Spain). LY341495 was
obtained from Tocris BioScience (Bristol, UK). Benzoylchloride,
Dulbecco’s modified Eagle’s medium (DMEM), glutamate, glutamine,
glutamate-d5 standards, glutamate-pyruvate transaminase (GPT), per-
tussis toxin (PTX) and sodium pyruvate were from Sigma–Aldrich (St.
Louis, MO, USA). Penicillin, streptomycin, L-Proline and G418 were
obtained from Duchefa Biochemie (Haarlem, The Netherlands). Fetal
calf serum (FCS) was from Biowest (Nuaillé, France). PET E-plates 16
and 96 for the xCELLigence DP and SP system (ACEA Biosciences, San
Diego, CA, USA) were obtained from Bioké (Leiden, the Netherlands).
Chinese hamster ovary cells (CHO-K1, CCL-61) were from ATCC
(Rockville, MD, USA). CHO-K1 cells stably expressing the hmGlu2 re-
ceptor (CHO-K1_hmGlu2) were from Janssen Research and
Development (Beerse, Belgium). Acetonitrile ULC/MS-grade was pur-
chased from Biosolve (Valkenswaard, The Netherlands). Formic acid
98–100% and disodium tetraborate decahydrate were obtained from
Merck (Darmstadt, Germany). High purity water was obtained with a
Milli–Q Reference Ultrapure Water Purification System (Merck
Millipore, Billerica, MA, USA). Other chemicals were of analytical grade
and from standard commercial sources.
2.2. Cell culture
CHO-K1_hmGlu2 cells were grown in DMEM supplemented with
10% (v/v) FCS, 200 IU·mL−1 penicillin, 200 µg·mL−1 streptomycin,
30.5 µg·mL−1 L-proline and 400 µg·mL−1 G418 at 37 °C and 5% CO2.
CHO-K1 WT cells were cultured in the same medium without G418.
2.3. Analysis of glutamate concentration
2.3.1. Preparation of stock solutions and curves
As glutamate is present in the culture medium as an endogenous
entity, a calibration curve had to be prepared in an artificial matrix, for
which demineralised water was used. Therefore, a quality check was
performed to validate quantification of the samples with a standard
addition step (a known amount of glutamate is spiked to a sample). The
calibration curve was prepared in a range of 0.010–50 µg/ml, starting
from a stock solution of 100 µg/ml glutamate in water. Glutamate-d5
was used as a stable isotope labelled internal standard (STIL).
2.3.2. Sample preparation
Glutamate was quantified after derivatization with benzoylchloride.
20 µL medium was transferred to a sample tube, subsequently 20 µL of
the calibration curve in water was added followed by 20 µL of STIL Glu-
d5 and 20 µL of NaBorate solution (100mM, pH 8). For derivatization,
40 µL benzoylchloride (3% v/v in acetonitrile) was transferred to the
sample tubes, after which samples were incubated for 15min at 50 °C
and subsequently cooled to room temperature for 10min. Finally,
200 µL 0.1% formic acid was added. Samples were vortexed and cen-
trifuged for 3min at 6000g, after which the supernatant was analyzed.
2.3.3. Liquid chromatography – Mass spectrometry
Chromatographic separation was performed with an Acquity UPLC
system (Waters, Millford, Boston, USA). Injections of 2 µL were made on
an Acquity UPLC BEH C18 2.1×50mm (1.7 µm particles) column held
at 55 °C at a flow rate of 0.400ml/min. Chromatographic elution
started isocratically at 2% solvent B (acetonitrile) and 98% solvent A
(0.1% formic acid) for 0.2 min. A subsequent linear gradient to 30% B
in 1.8min, followed by a wash step (0.2 min at 98% solvent B) and
0.8 min equilibration time at 2%B resulted in a total run time of 3min/
injection.
Instrument parameters were optimized by injecting a glutamate
standard solution (2 ng/ml in 0.1% formic acid/acetonitrile, v/v; 80/
20) at a flow rate of 10 μL/min. The following source parameters were
used: source temperature 150 °C, desolvation temperature 450 °C, ca-
pillary 2.9 kV, sampling cone 30 V, source offset 50 V, cone gas 150 L/h,
desolvation gas 900 L/h, collision gas flow 0.18ml/min and nebulizer
gas 6ml/min. Glutamate was analyzed in the positive ion mode with
electrospray ionization and detected by multiple reaction monitoring
(MRM) (collision energy 20 eV and dwell time 75ms) on a triple quad
Xevo TQ-s system (Waters, Manchester, UK), monitoring the channels
of m/z 252.1 - > 105.1 (quantifier) and m/z 252.1- > 130.1 (quali-
fier), respectively. The MRM transition monitored for the STIL Glu-d5 is
m/z 257.1 - > 105.1. During method optimization, special considera-
tion was given to the chromatographic separation of glutamate and
glutamine. The incubation medium has an excessive amount of gluta-
mine present and it is known that glutamine, with a MW 1Da lower
than glutamate, gives crosstalk in the MRM channel of glutamate.
Therefore, glutamine was also monitored, at m/z 251.1 - > 105.1 as a
qualifier. Quantitative values were obtained by relating chromato-
graphic peak areas to those derived from separately run calibration
standards as described above. Calibration curves were plotted using a
non-weighted log-log linear regression.
2.4. Label-free whole-cell assays
Label-free whole-cell assays were performed using the xCELLigence
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real-time cell analyzer (RTCA) system [3,34] as previously described
[7].
The system measures whole-cell responses based on changes in
electrical impedance generated by adherence of cells to gold-coated
electrodes at the bottom of microelectronic E-plates. Relative changes
in impedance (Z) are recorded continuously and displayed in the di-
mensionless parameter Cell Index (CI), which is defined as (Zi – Z0) Ω/
15Ω. Zi is the impedance at a given time and Z0 is the baseline im-
pedance measured at the start of the experiment in the absence of cells.
Z0 was measured after adding 45 µL, or in the case of pre-incubation
experiments 40 µL, culture medium per well in 16 or 96 well E-plates.
50 µL of cell suspension was added to the plate containing 40,000 cells
per well. After resting at room temperature for 30min, E-plates were
mounted in the recording station within a humidified 37 °C, 5% CO2
incubator. Subsequently, impedance was measured overnight every
15min. To remove endogenous glutamate, refreshment of culture
medium by culture medium or serum-free culture medium with GPT
(3 U/ml) and additional pyruvate (3 mM) was performed 3 h before
stimulation unless stated otherwise. For evaluation of constitutive re-
ceptor activity, pre-incubation with antagonist LY341495 or NAM
RO4491533 was performed 1 h before stimulation. After 19 h, cells
were stimulated with increasing concentrations of ligand (i.e. agonist,
antagonist, PAM or NAM). Final well volumes after addition of com-
pounds were 100 µL in all cases. DMSO concentrations were constant
between wells and were ≤0.1%. For inhibition of Gαi signaling, cells
were seeded in culture medium containing PTX (300 ng/ml) when in-
dicated. PTX concentrations were kept constant also after medium re-
freshment.
2.5. Data analysis
RTCA software 2.0 (ACEA Biosciences) was used to obtain the ex-
perimental data. All analyses were performed using Prism 7.00
(GraphPad software, San Diego, CA, USA). Ligand responses were
normalized to Δ cell index (ΔCI) after subtracting baseline (vehicle
control) to correct for ligand-independent effects. Maximum or
minimum peak responses were considered as the highest or lowest level
of ΔCI within 60min after compound stimulation and were used for bar
graphs and concentration-response curves. pEC50 and pIC50 values were
obtained using non-linear regression curve fitting into a sigmoidal dose-
response curve with variable slope. Data shown are the mean ± SEM
of at least three individual experiments performed in duplicate.
Statistical analyses were performed as indicated. If p-values were below
0.05, observed differences were considered statistically significant.
3. Results and discussion
3.1. Serum-free assay medium with GPT resulted in lowest levels of
endogenous glutamate
One of the benefits of the xCELLigence biosensor is that experiments
can be performed under more relevant conditions than most traditional
assays (i.e. living cells at 37 °C in culture medium). However, en-
dogenous glutamate is often found in culture medium and is also con-
tinuously produced by cells [35]. As high levels of glutamate will in-
terfere with functional responses by other mGlu2 receptor agonists, we
first determined the concentration of endogenous glutamate in culture
medium using HPLC analysis, which was found to be 78 ± 2.0 µM
(Table 1). Since the potency of glutamate to activate the mGlu2 receptor
is around 10 µM, this concentration is capable to activate the mGlu2
receptor to a high level [23,36]. Hence, we aimed to reduce the con-
centration of endogenous glutamate in the culture medium. For this
purpose, glutamate-pyruvate transaminase (GPT; 3 U/ml) was added in
the presence of additional pyruvate (3 mM), a procedure commonly
used in the field of mGlu receptors, e.g. [37,38]. This treatment led to
an almost 4-fold lower concentration of glutamate in the culture
medium: 23 ± 0.09 µM. At this concentration, glutamate is still able to
activate the receptor over 50% and will thus significantly interfere with
the functional readout. Next, we switched to serum-free medium, which
we determined to contain only 0.22 ± 0.005 µM endogenous gluta-
mate, indicating that the fetal calf serum (FCS) present in the culture
medium was the main source of glutamate.
Importantly, when seeded in serum-free medium, cells did not at-
tach to the bottom of the wells, did not proliferate and therefore did not
show any remarkable level of impedance (data not shown). This clearly
indicated that cells required FCS for growth and proliferation.
Therefore, serum-free medium was added to the wells by medium re-
freshment three hours before stimulation only. Of note, during these
first three hours of the serum-free medium being on the cells, the
concentration of glutamate increased to 13 ± 0.47 µM at the time of
stimulation (Table 1). Therefore, GPT and pyruvate were added to this
serum-free assay medium, resulting in a stable concentration of en-
dogenous glutamate during the signaling read-out of 1 h (i.e. from
1.6 ± 0.09 µM at the moment of stimulation to 2.3 ± 0.62 µM two
hours after stimulation, Table 1). This residual level of endogenous
glutamate only slightly activates the receptor to a maximum level of
approximately 10%, leaving a large experimental window for further
(exogenous) agonist-induced receptor signaling studies.
3.2. Endogenous glutamate reduced agonist yet enhanced antagonist
responses
The mGlu2 receptor-mediated signaling was monitored on the
xCELLigence RTCA system. In the field of class C GPCRs, this technique
was never characterized extensively, yet it was used as a tool in two
studies: Scandroglio et al. [39] presented a small proof of concept study
on the mGlu1 receptor and recently we reported on the mGlu2 receptor
using the xCELLigence as a tool to assess the effect of residence time on
functional efficacy of mGlu2 PAMs [40]. Here, CHO-K1_hmGlu2 cells
stably expressing the hmGlu2 receptor were used. 40,000 cells/well
were seeded in culture medium 19 h prior to stimulation (Fig. 1A). The
cells adhered well to the bottom of the wells on the gold-coated elec-
trodes, which is essential for sufficient measurements of impedance
[41]. Therefore no additional well coatings had to be used. Overnight
proliferation generally led to cell indices (CI) between 3 and 5 (Fig. 1B
for two representative traces), dependent on cell passage number and
confluency.
As discussed above, the concentration of endogenous glutamate
varied between different pre-treatment conditions (Table 1). To assess
how this affected the response of an mGlu2 receptor agonist or an-
tagonist, responses of a single 1 µM concentration of LY354740 and
LY341495 were obtained, respectively. This concentration was chosen
such that it is well above the respective potencies of the two ligands.
The traces of the agonist LY354740 at 1 µM were always “positive”,
inducing an increase in Cell Index and thus impedance (Fig. 1C,D). The
responses after different pre-treatment conditions varied greatly. When
using normal culture medium containing a high concentration of en-
dogenous glutamate at the time of stimulation (100 ± 3.0 µM), a small
LY354740 response was observed, with peaks at an average maximum
ΔCI level of 0.098 ± 0.012 (Fig. 1D). In the presence of GPT and
pyruvate the glutamate concentration was reduced to 28 ± 1.1 µM at
stimulation, resulting in an increased LY354740 response with max-
imum peaks of 0.24 ± 0.05 ΔCI. This response reached a similar
maximum level as when culture medium was replaced by serum-free
medium, although the LY354740 response was more prompt in that
case (Fig. 1C). The highest and significantly increased LY354740 re-
sponse was obtained using medium refreshment with serum-free
medium containing GPT and pyruvate, which contained 1.6 ± 0.09 µM
endogenous glutamate at the time of stimulation, leading to sig-
nificantly increased maximum peaks of 0.47 ± 0.04 ΔCI. Even in the
presence of a high concentration of endogenous glutamate, LY354740
was still able to induce responses (Fig. 1C, D), which exemplified the
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sensitivity of the xCELLigence system, registering very small ligand-
induced responses.
In contrast to the positive LY354740 responses, 1 µM antagonist
LY341495 induced opposite negative responses in Cell Index (Fig. 1E).
As for the agonist LY354740, the peak level (i.e. minimum peak in case
of LY341495) was dependent on the medium refreshment conditions,
although in reversed order. When using normal culture medium the
peak of LY341495 was the largest, −1.62 ± 0.06 ΔCI (Fig. 1F).
Treatment of culture medium with GPT already reduced the peak
slightly, but when medium was refreshed by serum-free medium peaks
were significantly reduced to minimum levels of −0.92 ± 0.08 ΔCI.
Moreover, addition of GPT did not further increase the minimum peak
of LY341495 (−0.98 ± 0.06 ΔCI, Fig. 1F), indicating a relatively large
response of the compound on its own. Interestingly, in serum-free
medium with GPT, the trace returned to baseline more readily after the
peak (Fig. 1E), indicating that the difference in glutamate levels still
slightly altered the shape of the trace. Importantly, no compound-in-
duced responses were observed for both LY354740 and LY341495 at
1 µM in parental wild-type CHO-K1 cells (Fig. 1C, E), confirming that all
responses were mGlu2 receptor-mediated. This was in line with our
previous observation that PAM JNJ-46281222 did not induce sig-
nificant responses on parental CHO-K1 cells [42].
Taken together, the lowest level of endogenous glutamate was
reached by medium refreshment with serum-free medium supple-
mented with GPT, which was used for all further experiments. Of note,
the presence of the glutamate degrading enzyme GPT excluded further
experimentation with exogenous glutamate, since such experiments
would not result in meaningful parameters for potency and/or efficacy.
The responses of LY354740 and LY341495 were affected by the dif-
ferent endogenous glutamate concentrations from the culture medium.
LY354740 peaks increased upon reduction of endogenous glutamate
levels. On the contrary, LY341495 peaks were reduced when en-
dogenous glutamate levels were lowered. Both observations indicate
competition of the two molecules for the orthosteric glutamate binding
site, which has been shown in radioligand binding experiments with
[3H]LY354740 and [3H]LY341495 as the radioligands [43,44].
3.3. Agonist LY354740 and antagonist LY341495 induced concentration-
dependent responses at low levels of endogenous glutamate
Once the assay conditions were optimized, the potency of agonist
LY354740 and antagonist LY341495 were determined. For LY354740
the impedance increased concentration-dependently with a “positive”
peak (i.e. positive ΔCI values) around 10min, then gradually decreasing
with a second ‘shoulder’ peak around 20min (Fig. 2A). A concentration-
response curve obtained from the maximum peak levels within the first
60 min after stimulation revealed a pEC50 value of 6.70 ± 0.24
(Table 2; Fig. 2B). This potency was lower than observed in other assay
types such as Ca2+ mobilization (pEC50 7.4; [45]) and similar to the
potency obtained in electrophysiology experiments on hippocampal
slices (pEC50 6.9; [46]).
Stimulation with increasing concentrations of the antagonist
LY341495 resulted in concentration-dependent negative peaks with a
minimum around 15min (Fig. 2A). For low concentrations it took
around 30min to return to baseline, while at 0.1 and 1 µM LY341495
the trace returned to baseline after 120 or 180min, respectively (data
not shown). A pIC50 value of 8.15 ± 0.09 was obtained from the
minimum peak levels (Fig. 2B; Table 2), which was in agreement with
potencies reported before using cAMP, Ca2+-mobilization and
[35S]GTPγS assays [14,31]. The concentration-response curve of
LY354740 had a pseudo-Hill coefficient of around unity (nH 0.92)
compared to the curve of LY341495 that was much steeper (nH −1.81).
As mentioned before, LY341495 showed negative responses in Cell
Index, indicating that it exhibits an opposite pharmacological effect
compared to the agonist LY354740, resulting in an opposite impedance
measured. Similar observations have been seen using other label-free
systems (i.e. the CellKey and EPIC system), in which agonists induced
an increase in response, while inverse agonists caused a decrease in
response [1,47]. However, these studies do not present a mechanistic
understanding as they were performed on two non-disclosed GPCRs.
Given that in these studies inverse agonists induced negative responses,
LY341495 may also be an inverse agonist at the mGlu2 receptor,
especially since the concentration of endogenous glutamate was re-
duced to a level only slightly able to activate the receptor.
Finally, the selective Gαi/o inhibitor PTX was used to evaluate
whether the effects induced by the agonist LY354740 and antagonist
LY341495 were mediated via Gαi/o protein-dependent signaling.
Responses of LY354740 and LY341495 were almost completely lost in
the presence of PTX, which indicated that the opposite compound-in-
duced cellular responses were both resulting from signaling via Gαi/o
(Fig. 2C,D). The residual responses in the presence of PTX most likely
represent incomplete inhibition of the Gαi/o-mediated signaling.
3.4. Agonist efficacy was increased by PAM and decreased by NAM
treatment
Before measuring the effect of allosteric modulators on agonist ef-
ficacy, responses of a PAM and a NAM in the absence of exogenous
agonist were determined. Both allosteric modulators showed responses
on their own without added agonist, which were likely caused by the
low level of endogenous glutamate (1.6 ± 0.09 µM) still present in the
serum-free culture medium with GPT (Table 1). Stimulation with the
PAM JNJ-46281222 resulted in positive dose-dependent responses,
leading to a pEC50 of 7.17 ± 0.24 for this compound (Table 2; Fig. 3A,
B). The potency of the PAM was lower than in a [35S]GTPγS assay
(pEC50 of 7.71; [23]). This may be caused by the concentration of en-
dogenous glutamate that is lower than the typical EC20 glutamate
concentrations used in standard [35S]GTPγS assays used to determine
the potency of allosteric modulators or by the differences in assay types
[48,49]. Treatment with the NAM RO4491533 induced negative peaks
in Cell Index yielding a pIC50 value of 7.34 ± 0.19, which was lower
than observed before in a [35S]GTPγS assay (pIC50 8.7; [48]). In this
case the difference may be due to the high EC80 glutamate concentra-
tion used in the [35S]GTPγS assay or, again, due to the differences in
Table 1
Glutamate concentrations (µM) in culture medium or serum-free medium with and without addition of GPT (3 U/ml) and pyruvate (3 mM). Medium was added to the
cells at the time of medium refreshment (−3 hrs).
Time of: Time from stimulation (hrs) Culture medium Serum-free medium
− GPT + GPT − GPT + GPT
Medium refreshment −3 78 ± 2.0 23 ± 0.09 0.22 ± 0.005 0.098 ± 0.004
−2.5 83 ± 1.6 23 ± 0.58 3.7 ± 0.20 1.2 ± 0.09
Pre-treatment −1 88 ± 1.3 25 ± 0.90 9.8 ± 0.09 1.2 ± 0.10
Stimulation 0 100 ± 3.0 28 ± 1.1 13 ± 0.47 1.6 ± 0.09
2 100 ± 9.4 33 ± 1.9 17 ± 2.1 2.3 ± 0.62
Data are shown as mean ± SEM of at least three individual experiments performed in duplicate.
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assay type. The concentration-response curve of JNJ-46281222 was
shallow with a pseudo-Hill coefficient of 0.59 compared to
RO4491533’s which was around unity (nH −1.02). Of note, this is the
first observation that Cell Indices go up in the presence of a PAM and
down when using a NAM, like JNJ-46281222 and RO4491533, re-
spectively. In that sense, the effects of allosteric modulators for the
mGlu2 receptor resemble orthosteric compound-induced responses as
described above.
To study the effects of a PAM on agonist efficacy, cellular responses
to an LY354740 concentration equivalent to its EC20 response (30 nM)
were determined in the absence and presence of 1 µM JNJ-46281222.
This resulted in a significant 3-fold increase in the LY354740 peak
Fig. 1. Agonist LY354740 and antagonist LY341495-induced responses in the presence of different concentrations of endogenous glutamate. A) Set-up of experi-
ments. B) Typical growth curve of CHO-K1 cells stably expressing the mGlu2 receptor (40,000 cells/well). 3 h prior to stimulation culture medium was replaced by
serum-free medium containing GPT (3 U/ml) and additional pyruvate (3 mM). Cells were stimulated with LY354740 (1 µM). Serum-free medium with 0.025% DMSO
was used as vehicle control. C) Responses induced by 1 µM LY354740 after different pre-treatment conditions and the response of 1 µM LY354740 on CHO-K1 WT
cells three hours after replacement of culture medium by serum-free medium containing GPT. D) Maximum peak values induced by 1 µM LY354740 in the presence of
different concentrations of endogenous glutamate as presented in Table 1. E) Responses induced by 1 µM LY341495 after different pre-treatment conditions and the
response of 1 µM LY341495 on CHO-K1 WT cells three hours after replacement of culture medium by serum-free medium containing GPT. F) Maximum peak values
induced by 1 µM LY341495 in the presence of different concentrations of endogenous glutamate as presented in Table 1. All xCELLigence traces are from re-
presentative experiments performed in duplicate. Bar graphs represent mean ± SEM of at least three individual experiments performed in duplicate. Statistical
analyses were performed using one-way ANOVA with Tukey’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001.
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response, confirming that JNJ-46281222 behaves as a PAM for this
agonist (Fig. 3C). The effect of 1 µM of the NAM RO4491533 was de-
termined using an LY354740 concentration equivalent to its EC80
concentration (300 nM). This yielded a significant, more than twofold
reduction in the response of LY354740 (Fig. 3D), which is a typical
NAM effect. These experiments showed that xCELLigence is able to
assess the effects of allosteric modulators on agonist efficacy, which is
in line with work reported by Chen et al. [50] on allosteric modulation
of the M4 muscarinic acetylcholine receptor.
3.5. LY341495 pre-treatment revealed constitutive receptor activity
The maximum peak height of the agonist LY354740 was much
lower compared to the negative peaks of the antagonist LY341495
(Fig. 2A, C). In order to study the underlying mechanism, cells were
pretreated with 1 µM LY341495 1 h prior to stimulation (Fig. 4A). The
response of subsequent stimulation by 1 µM LY354740 was increased
significantly from an average max peak of 0.47 ± 0.04 ΔCI up to a
level of 1.21 ± 0.16 (Fig. 4B, C). This was opposite to the expected loss
of agonist response by the pre-treatment with a high concentration of a
competitive antagonist that is still present at the time of stimulation
with agonist. The effect of LY341495 pre-treatment on the LY354740
peak was concentration-dependent: pre-treatment with 10 nM
LY341495 slightly increased LY354740 traces, whereas 100 nM and
1 µM LY341495 were able to further and significantly increase the peak
height of 1 µM LY354740 stimulation (Fig. 4C). All traces reached
baseline after 30–45min. In contrast to the other traces, the trace of
1 µM LY354740 after pre-treatment with 1 µM LY341495 increased
slightly after that point reaching a plateau around 0.4 ΔCI. Treatment
with the selective Gαi/o inhibitor PTX revealed that the LY354740 re-
sponse after pre-treatment with LY341495 was lost in the presence of
PTX, indicating that this is also a mostly, if not fully, Gαi/o-mediated
response (Fig. 4B, C). In contrast to LY341495, pre-treatment with 1 µM
of the NAM RO4491533 resulted in a typical reduced agonist response
of LY354740 (Fig. 4D, E).
Together, these results show that LY341495 increased the window
of agonist response by almost 3-fold. This is a larger increase than can
be explained by the level of endogenous glutamate (1.6 µM at stimu-
lation), which might enable approximately 10% receptor activation.
Blockade of glutamate binding may thus increase the agonist-induced
response by a similar level. Therefore, we believe that the increased
agonist response after pre-treatment with LY341495 indicates that the
receptor is constitutively active and that LY341495 is behaving as an
inverse agonist. This was confirmed by the fact that, in contrast to pre-
treatment with LY341495, pre-treatment by the NAM RO4491533 re-
sulted in a decreased agonist response (Fig. 4D, E). Such a decreased
agonist response is similar to the expected effect of pre-treatment with a
Fig. 2. Agonist LY354740 and antagonist LY341495-induced concentration-effect responses at low concentration of endogenous glutamate (1.6 ± 0.09 µM). A) Cells
were stimulated by increasing concentrations of agonist LY354740 or antagonist LY341495. B) Concentration-response curves were obtained from maximum
(LY354740) or minimum (LY341495) ΔCI values and normalized from vehicle-induced ΔCI (0%) to maximum or minimum ΔCI (100% or -100% respectively). C)
Responses of 1 µM LY354740 and 1 µM LY341495 in the absence or presence of PTX (300 ng/ml). D) Comparison of maximum peak values induced by 1 µM
LY354740 and minimum peak values induced by 1 µM LY341495 in the absence or presence of PTX (300 ng/ml). All xCELLigence traces are from representative
experiments performed in duplicate. Concentration-response curves (panel B) represent mean ± SEM of at least three individual experiments performed in du-
plicate. Bar graphs represent mean ± SEM of at least three individual experiments performed in duplicate. Statistical analysis was performed using a two-tailed
unpaired Student’s t-test. *p < 0.01, **p < 0.001.
Table 2
Potency (pEC50 or pIC50) of ligands at the mGlu2 receptor in CHO-K1_hmGlu2
cells after refreshment of medium by serum-free medium containing GPT (3 U/
ml) and pyruvate (3mM).
Compound pEC50 pIC50
LY354740 Agonist 6.70 ± 0.24 –
LY341495 Antagonist – 8.15 ± 0.09
JNJ-46281222 PAM 7.17 ± 0.24 –
RO4491533 NAM – 7.34 ± 0.19
pEC50/IC50 data are shown as mean ± SEM from at least three individual ex-
periments performed in duplicate.
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neutral antagonist.
To further assess the inverse agonism of LY341495, concentration-
response curves were obtained after pre-treatment with increasing
concentrations of the PAM JNJ-46281222 (Fig. 4F, G). The curves
shifted from a pIC50 of 8.15 ± 0.09 without PAM pre-treatment to
7.89 ± 0.13 in the presence of 10 nM PAM, to 7.55 ± 0.13 in the
presence of 100 nM PAM. Such a modulatory shift in potency in the
presence of a PAM is typical for an inverse agonist and is not expected
for a neutral antagonist [51,52]. Next to the shift in potency, increasing
concentrations of PAM pre-treatment resulted in a larger window of
LY341495 response. On the contrary, pre-treatment with NAM
RO4491533 did not result in significant alteration in LY341495 potency
(Fig. 4H), a pIC50 values of 8.22 ± 0.14 in the presence of 100 nM
NAM and 8.35 ± 0.12 in the presence of 1 µM NAM were found. The
efficacy window of LY341495 was reduced dose-dependently up to
more than 60% at 1 µM NAM, showing that the NAM is not only able to
strongly reduce agonist efficacy without changing potency [31], but
similarly affects the inverse agonist activity of LY341495.
A shift in LY341495 potency induced by the PAM could be the
reason of increased potency of endogenous glutamate. However, the
large shift in efficacy cannot be explained by presence of endogenous
agonist, nor can the large reduction of efficacy after NAM pre-treat-
ment. Together, inverse agonism by LY341495 was further confirmed
by these PAM and NAM pre-treatment experiments in this system that
measures phenotypic morphological responses of the whole cell, in this
case via the Gαi/o signaling pathway. On a separate note, receptor de-
sensitization induced by endogenous glutamate could be of concern
here. However, the mGlu2 receptor is known to be resistant to agonist-
induced desensitization which was also seen in our hands in repeated
stimulation experiments (data not shown) [53,54]. Doumazane et al.
(2013) [55] found a higher FRET signal after application of 1 µM
LY341495, similar to the effect of LY341495 pre-treatment presented
here. These authors reasoned that this effect was mediated by either
constitutive activity or presence of endogenous glutamate, which was
not elucidated any further. Inverse agonism by LY341495 has been
reported before. For example, DiRaddo et al. (2014) [56] found that
LY341495 was behaving as inverse agonist after pre-treatment with
agonist, when using the Glo-sensor cAMP assay with CHO-K1 cells
stably expressing the mGlu2 receptor. Moreover, inverse agonism by
LY341495 at the mGlu2 receptor was also seen in studies investigating
receptor cross-signaling in mGlu2-5HT2A heterocomplexes [57,58].
Generally, LY341495 is considered a neutral antagonist for the mGlu2
receptor [14,15] as most in vitro assays did not yield inverse agonism,
which is likely due to differences in cell lines or assay systems used.
In conclusion, we have validated the use of the impedance-based
biosensor xCELLigence system to study mGlu2 pharmacology. High le-
vels of endogenous glutamate reduced the agonist activation window
and therefore efforts were made to reduce these. We characterized
mGlu2 signaling with an agonist, antagonist and both positive and ne-
gative allosteric modulators; the latter two modulated the response of
both orthosteric agonist and antagonist. Remarkable and opposite ef-
fects on impedance were observed for compounds with opposite phar-
macological effects. Both the agonist and PAM increased impedance
whereas the antagonist and NAM decreased this read-out. Importantly,
Fig. 3. Positive allosteric modulator (PAM) JNJ-46281222 and negative allosteric modulator (NAM) RO4491533-induced responses at low concentration
(1.6 ± 0.09 µM) of endogenous glutamate. A) Cells were stimulated by increasing concentrations of JNJ-46281222 or RO4491533. B) Concentration-response
curves were obtained from maximum (JNJ-46281222) or minimum (RO4491533) ΔCI values and normalized from vehicle-induced ΔCI values (0%) to maximum
(100%) or minimum (−100%) ΔCI values. C) Responses induced by an EC20 LY354740 concentration in the absence and presence of 1 µM JNJ-46281222. D)
Responses induced by an EC80 LY354740 concentration in the absence and presence of 1 µM RO4491533. xCELLigence traces are from representative experiments
performed in duplicate. Bar graphs represent mean ± SEM of at least three experiments performed in duplicate, where data was normalized to the response of PAM
or NAM on itself (1.0). Statistical analysis was performed using a two-tailed unpaired Student’s t-test. *p < 0.01, **p < 0.001.
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we show that constitutive mGlu2 receptor activity could be inhibited by
the antagonist LY341495 which therefore behaved as an inverse agonist
in the system used. The present study provides an extended ensemble of
the properties of mGlu2 ligands in comparison to conventional in vitro
assays. Together the results show that label-free biosensors, such as the
xCELLigence, are valuable tools in drug discovery and pharmacological
profiling at the mGlu2 receptor as well as other GPCRs.
Fig. 4. Evaluation of LY341495 inverse agonism. A) Set-up of experiments. B) Cells were stimulated with 1 µM LY354740 after pre-treatment with increasing
concentrations of LY341495. Pre-treatment with 1 µM LY341495 was also performed in the presence of PTX (300 ng/ml). C) Comparison of maximum peak values
induced by 1 µM LY354740 after pre-treatment with increasing concentrations of LY341495. Pre-treatment with 1 µM LY341495 was also performed in the presence
of PTX (300 ng/ml). D) Cells were stimulated with 1 µM LY354740 after pre-treatment with 1 µM NAM RO4491533 or vehicle. E) Comparison of maximum peak
values induced by 1 µM LY354740 after pre-treatment with 1 µM RO4491533 or vehicle. F) Set-up of experiments. G, H) Concentration-response curves were
obtained from minimum ΔCI values and normalized from vehicle-induced ΔCI values (0%) to minimum (−100%) ΔCI values after vehicle pre-treatment.
xCELLigence traces are from representative experiments performed in duplicate. Bar graphs represent mean ± SEM of at least three individual experiments per-
formed in duplicate. Concentration-response curves represent mean ± SEM of at least three individual experiments performed in duplicate. Statistical analysis was
performed using a one-way ANOVA with Dunnett’s (C) post-test or using a two-tailed unpaired Student’s t-test (E). *p < 0.01, **p < 0.001, ***p < 0.0001.
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